US Bancorp
AXDX

US Bancorp’s Accelerate Diagnostics AXDX Stock Holding History

US Bancorp’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-165
Closed -$9K – 4060
2021
Q4 		$9K Buy
+165
New +$9.19K ﹤0.01% 3449
2021
Q3 		– Sell
-4
Closed – – 4072
2021
Q2 		$0 Buy
+4
New +$318 ﹤0.01% 3991
2021
Q1 		– Sell
-9
Closed -$1K – 3874
2020
Q4 		$1K Buy
9
+2
+29% +$179 ﹤0.01% 3643
2020
Q3 		$1K Buy
+7
New +$972 ﹤0.01% 3560
2017
Q1 		– Sell
-169
Closed -$35K – 3546
2016
Q4 		$35K Hold
169
– – ﹤0.01% 2612
2016
Q3 		$46K Sell
169
-252
-60% -$55.8K ﹤0.01% 2477
2016
Q2 		$61K Buy
421
+278
+194% +$37.3K ﹤0.01% 2297
2016
Q1 		$21K Buy
143
+26
+22% +$3.67K ﹤0.01% 2732
2015
Q4 		$25K Buy
117
+65
+125% +$11.9K ﹤0.01% 2741
2015
Q3 		$8K Buy
+52
New +$11.3K ﹤0.01% 3132

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

US Bancorp's AXDX Position: Q1 2022 in Review

US Bancorp sold out of Accelerate Diagnostics (AXDX) in Q1 2022, closing a stake of 165 shares — an estimated $9K sold.

US Bancorp first reported a position in AXDX in Q3 2015 and held it in 10 quarters. The position peaked at $61K in Q2 2016. 106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

  • US Bancorp reported no remaining Accelerate Diagnostics position as of Q1 2022 after selling out during the quarter.
  • US Bancorp sold 165 Accelerate Diagnostics shares in Q1 2022, an estimated $9K.
  • US Bancorp first reported a position in Accelerate Diagnostics in Q3 2015 and held it in 10 quarters.
  • US Bancorp's Accelerate Diagnostics position peaked at $61K in Q2 2016.
  • 106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.